NRIXNurix Therapeutics, Inc.

NRIX Stock Price, Valuation & Chart | Nurix Therapeutics, Inc.

Compare

$26.950+0.68 (+2.59%)

At close · 25 Aug 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology NRIX intrinsic value Is NRIX overvalued or undervalued

Overview Financials Dividends Ratios

NRIX Historical price chart

NRIX Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization2.80B

PE Ratio-7.81

EPS-3.45

Trading Volume1.49M

Today's High/Low27.38/26.38

Dividend Yield0.00

52 Week High/Low28.23/8.2

Shares Outstanding103.78M

NRIX Financial Statement

NRIX Analyst ratings

NRIX Analysis & performance metrics

NRIX Company profile

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer…

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK…

NRIX Management team

Name

Position

Arthur T. Sands M.D., Ph.D.CEO

Chief Executive Officer, President & Director

Christine Ring J.D., Ph.D.

Chief Legal Officer, Secretary & Chief Compliance Officer

John Kuriyan Ph.D.

Founder & Member of Scientific Advisory Board

Arthur Weiss M.D., Ph.D.

Founder & Member of Scientific Advisory Board

Christopher B. Phelps Ph.D.

Senior Vice President & Head of Early Drug Discovery

Pasit Phiasivongsa Ph.D.

Chief Technical Officer

Jason Kantor Ph.D.

Chief Business Officer

Rita Kwong

Senior Accounting Manager

Name

Position

Arthur T. Sands M.D., Ph.D.CEO

Chief Executive Officer, President & Director

Christine Ring J.D., Ph.D.

Chief Legal Officer, Secretary & Chief Compliance Officer

John Kuriyan Ph.D.

Founder & Member of Scientific Advisory Board

Arthur Weiss M.D., Ph.D.

Founder & Member of Scientific Advisory Board

Christopher B. Phelps Ph.D.

Senior Vice President & Head of Early Drug Discovery

Pasit Phiasivongsa Ph.D.

Chief Technical Officer

Jason Kantor Ph.D.

Chief Business Officer

Rita Kwong

Senior Accounting Manager

Management Team

Arthur T. Sands M.D., Ph.D.CEO

Chief Executive Officer, President & Director

Christine Ring J.D., Ph.D.

Chief Legal Officer, Secretary & Chief Compliance Officer

John Kuriyan Ph.D.

Founder & Member of Scientific Advisory Board

Arthur Weiss M.D., Ph.D.

Founder & Member of Scientific Advisory Board

Christopher B. Phelps Ph.D.

Senior Vice President & Head of Early Drug Discovery

Pasit Phiasivongsa Ph.D.

Chief Technical Officer

Jason Kantor Ph.D.

Chief Business Officer

Rita Kwong

Senior Accounting Manager

Management

Arthur T. Sands M.D., Ph.D.CEO

Chief Executive Officer, President & Director

Christine Ring J.D., Ph.D.

Chief Legal Officer, Secretary & Chief Compliance Officer

John Kuriyan Ph.D.

Founder & Member of Scientific Advisory Board

Arthur Weiss M.D., Ph.D.

Founder & Member of Scientific Advisory Board

Christopher B. Phelps Ph.D.

Senior Vice President & Head of Early Drug Discovery

Pasit Phiasivongsa Ph.D.

Chief Technical Officer

Jason Kantor Ph.D.

Chief Business Officer

Rita Kwong

Senior Accounting Manager

Total 8 executives

NRIX Frequently asked questions

What is Nurix Therapeutics, Inc. (NRIX) Stock Price?

Current stock price of Nurix Therapeutics, Inc. (NRIX) stock is $26.950. The stock price is +2.59% higher in the session. The intraday range can be seen from this page. Volume of Nurix Therapeutics, Inc. (NRIX) stock is 1.49M.

Last updated at 25 Aug 2026, 08:00 pm.

Why is the Nurix Therapeutics, Inc. (NRIX) stock price going up or down today?

The stock price of Nurix Therapeutics, Inc. (NRIX) can change with earnings, company news, and overall market sentiment. Nurix Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Nurix Therapeutics, Inc. stock expensive at its current price?

Whether Nurix Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for NRIX on this page is -7.81. EPS on this page is -3.45. Compare those figures with peers and growth expectations before deciding if the current Nurix Therapeutics, Inc. price is justified.

How has the stock price of Nurix Therapeutics, Inc. (NRIX) performed historically?

Historical performance for Nurix Therapeutics, Inc. (NRIX) is shown on the price chart on this page. Review multi-period moves alongside volume to see how NRIX reacted to past earnings and market events.

Should I buy Nurix Therapeutics, Inc. (NRIX) stock, at this price?

Buying Nurix Therapeutics, Inc. (NRIX) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.